News regarding NextCell Pharma.

 

Today NextCell Publishes its half-year report

NextCell Pharma AB ("NEXTCL", "NextCell") today released its half-year report (September 1, 2017 - February 28, 2018)

Läs mer

NextCell enters into Memorandum of Agreement with China General Consulting & Investment Co., Ltd.

NextCell Pharma AB ("NextCell") hereby announces that the company has entered a Memorandum of Agreement with China General Consulting & Investment Co., Ltd. (”CGCI”). The purpose of the agreement is to create a base for future co-operation. The agreement includes that the parties should prioritize working together when it comes to stem cell development and…

Läs mer

The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.

Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the medium-dose cohort.

Läs mer

An update on NextCell Pharma and Nordic Tech House

NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights.

Läs mer

Nordic Tech House to invest in stem cell company NextCell Pharma

NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva.

Läs mer

NextCell CEO invited speaker at the Swedish National ATMP Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th.

Läs mer

Three patients now treated with NextCells ProTrans stem cells

NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now undergone treatment.

Läs mer

NextCell Pharma files patent application

NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans.

Läs mer

NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL.

Läs mer

First diabetes patient treated with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years.

Läs mer

NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans

NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40…

Läs mer

Today Nextcell Pharma publishes its annual report 2016-2017

NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com

Läs mer

NextCell Pharma updates on its situation in its fourth quarter report

NextCell Pharma AB ("NEXTCL", "NextCell") today releases its Q4 / year-end report (June 1st - August 31st  / September 1st - August 31st). This is the first quarterly report since the listing on Aktietorget. The company reports a loss of SEK -4,757,996 in its fourth quarter and a loss of SEK -13,245,206 for the entire…

Läs mer

NextCell Pharma's stem cell study in Type 1 Diabetes gets green light from the Medical Products Agency

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans.

Läs mer

Family saving of stem cells at Underbara Barn held atStockholm International Fair and Congresses Centre,13-15 October, 2017

For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from the umbilical cord. Cellaviva is Sweden's first and…

Läs mer

 

Contact

Karolinska Institutet Science Park
Hälsovägen 7, 141 57 Huddinge
info@nextcellpharma.com
+46 (0)8 735 55 95